Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL9229142 | 0.96 | LMNA (0.51) | LMNANR3C2NR3C1MGLLALDH1A1 | |
| SCHEMBL7299793 | 0.88 | LMNA (0.59) | LMNANR3C2NR3C1ALDH1A1NPSR1 | |
| SCHEMBL9079122 | 0.87 | LMNA (0.50) | LMNANR3C2NR3C1MGLLCCR2 | |
| SCHEMBL7301998 | 0.84 | LMNA (0.53) | LMNANR3C2NR3C1MGLLALDH1A1 | |
| SCHEMBL7298261 | 0.84 | LMNA (0.58) | LMNANR3C2NR3C1MGLL | |
| SCHEMBL7300845 | 0.84 | LMNA (0.58) | LMNANR3C2NR3C1MGLL | |
| SCHEMBL8544144 | 0.82 | LMNA (0.53) | LMNANR3C2NR3C1MGLLNPSR1 | |
| SCHEMBL7305405 | 0.78 | LMNA (0.51) | LMNANR3C2NR3C1ALDH1A1NPSR1 | |
| SCHEMBL7304686 | 0.76 | LMNA (0.48) | LMNANR3C2NR3C1MGLLALDH1A1 | |
| SCHEMBL7299161 | 0.76 | LMNA (0.71) | LMNANR3C2NR3C1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666260-B1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1999-08-04 | — | — | EP | disclosed |
| US-5550125-A | BRAIN DISORDERS | SYNTHELABO (FR) | 1996-08-27 | — | — | US | disclosed |
| EP-0666260-A1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1995-08-09 | — | — | EP | disclosed |